Tag : ATEZOLIZUMAB

CONFERENCE UPDATE

Intravesical rBCG + chemo-immunotherapy achieves high complete response rates in MIBC: Phase 2 SAKK 06/19 trial
The phase 2 SAKK 06/19 study demonstrated that adding intravesical recombinant BCG (rBCG) to perioperative cisplatin/gemcitabine + atezolizumab achieved a high pathological complete response (pCR) rate in patients with muscle-invasive bladder cancer (MIBC) while maintaining a feasible and tolerable safety profile, supporting further evaluation of this multimodal strategy in randomized clinical trials.
CONFERENCE UPDATE

Resectable NSCLC in transition: Integrating immunotherapy and targeted approaches
The landscape of early-stage non-small cell lung cancer is undergoing a rapid transformation. Once defined by the modest survival gains of adjuvant chemotherapy, treatment strategies now extend to immunotherapy and targeted therapies in both adjuvant and neoadjuvant settings.